Osang Healthcare Co.,Ltd (036220.KQ)
KRW 12930.0
(-0.54%)
KRW 12930.0
(-0.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 355.84 Billion KRW | 83.53% |
| 2022 | 193.89 Billion KRW | 46.53% |
| 2021 | 132.32 Billion KRW | -48.7% |
| 2020 | 257.96 Billion KRW | 350.45% |
| 2019 | 57.26 Billion KRW | 2.0% |
| 2018 | 56.14 Billion KRW | 3.32% |
| 2017 | 54.33 Billion KRW | -8.01% |
| 2016 | 59.07 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 19.99 Billion KRW | -3.32% |
| 2024 Q1 | 20.68 Billion KRW | 41.71% |
| 2023 Q1 | 285.54 Billion KRW | 525.66% |
| 2023 Q4 | 14.59 Billion KRW | -27.17% |
| 2023 Q3 | 20.04 Billion KRW | -43.8% |
| 2023 Q2 | 35.66 Billion KRW | -87.51% |
| 2023 FY | 355.84 Billion KRW | 83.53% |
| 2022 Q2 | 47.74 Billion KRW | -32.82% |
| 2022 FY | 193.89 Billion KRW | 46.53% |
| 2022 Q4 | 45.63 Billion KRW | 55.05% |
| 2022 Q3 | 29.43 Billion KRW | -38.35% |
| 2022 Q1 | 71.07 Billion KRW | 98.3% |
| 2021 Q3 | 33.12 Billion KRW | 0.0% |
| 2021 FY | 132.32 Billion KRW | -48.7% |
| 2021 Q4 | 35.83 Billion KRW | 8.2% |
| 2020 FY | 257.96 Billion KRW | 350.45% |
| 2019 FY | 57.26 Billion KRW | 2.0% |
| 2018 FY | 56.14 Billion KRW | 3.32% |
| 2017 FY | 54.33 Billion KRW | -8.01% |
| 2016 FY | 59.07 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| InBody Co.,Ltd | 170.35 Billion KRW | -108.89% |
| Curexo Inc. | 72.88 Billion KRW | -388.249% |
| Seegene, Inc. | 367.37 Billion KRW | 3.138% |
| i-SENS, Inc. | 265.12 Billion KRW | -34.221% |
| Ray Co., Ltd. | 145.88 Billion KRW | -143.928% |
| Gencurix Inc. | 2.6 Billion KRW | -13584.747% |
| Sugentech Inc. | 7.13 Billion KRW | -4889.227% |
| L&C Bio Co., Ltd | 68.86 Billion KRW | -416.697% |